Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals

Junyeong Jin a,b,1, Changhoon Park c,1, Sun-Hee Cho c, Junho Chung a, b, d, *

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

A R T I C L E   I N F O

Article history:
Received 18 January 2018
Accepted 23 January 2018
Available online 31 January 2018

Keywords:
Decoy epitope
Vaccine
Porcine circovirus type 2
Capsid protein
Virus-like particle

A B S T R A C T

Viral pathogens have evolved a wide range of tactics to evade host immune responses and thus propagate effectively. One efficient tactic is to divert host immune responses toward an immunodominant decoy epitope and to induce non-neutralizing antibodies toward this epitope. Therefore, it is expected that the amount of decoy epitope in a subunit vaccine can affect the level of neutralizing antibody in an immunized animal. In this study, we tested this hypothesis by generating an antibody specific to the decoy epitope on the capsid protein of porcine circovirus type 2 (PCV2). Using this antibody, we found that two commercial vaccines contained statistically different amounts of the decoy epitope. The vaccine with lower levels of decoy epitope induced a significantly higher level of neutralizing antibody after immunization. This antibody can be used as an analytical tool to monitor the quality of a vaccine from batch to batch.

1. Introduction

Viral pathogens have evolved a wide range of tactics to evade host immune responses and propagate effectively [1]. One such tactic is to divert the host immune response with a decoy. Decoy epitopes have been reported in a wide variety of viruses, including human immunodeficiency virus (HIV) [2], feline immunodeficiency virus (FIV) [3], hepatitis C [4], foot and mouth disease [5], middle-east respiratory syndrome coronavirus [6], severe fever with thrombocytopenia syndrome virus [7], porcine reproductive and respiratory syndrome virus (PRRSV) [8], murine gammaherpesvirus-68 (MHV-68) [9], and porcine circovirus type 2 (PCV2) [10]. Because a recombinant mutant capsid protein (CP) with a deleted decoy epitope induced a higher level of virus-neutralizing antibody than wild type proteins [11], it was expected that higher levels of decoy epitope in a prepared batch of subunit vaccine would decrease its efficacy. However, it was not possible to test this hypothesis by measuring levels of decoy epitope in a vaccine because an antibody specific to the decoy epitope was not readily available.

PCV2 has a spherical structure with icosahedral symmetry [12]. The only structural protein of this virus is a 28-kD CP, which includes major antigenic determinants that can be used in subunit vaccines [13]. A previous study showed that an epitope composed of amino acid residues 169–180 (CP169–180) is the most immunodominant among these antigenic determinants [11]. Because this epitope is buried inside the virus-like particle (VLP) structure (Fig. 1A), antibodies to this epitope cannot react with the intact virus, and therefore are non-neutralizing [14]. As expected, PCV2 infection elicited a humoral response to the CP169–180 epitope and drove the production of non-neutralizing antibodies [15]. Therefore, previous infection with PCV decreased the vaccines prevention of the future infections.

Since the first vaccine against PCV2 was introduced to the global market in 2006, nine PCV2 subunit vaccines have become available [16]. However, they were expected to contain differing amounts of incomplete VLPs, which are non-uniformly aggregated CPs with an exposed CP169–180 epitope [17]. Incomplete VLPs can induce production of non-neutralizing antibodies and reduce vaccine efficacy [14,18]. As there was no analytical tool to measure the amount of CP169–180 epitope in a prepared batch of vaccine, it was not possible...
to correlate epitope levels with neutralizing activity after vaccination.

In this study, we developed an antibody specific to the CP169e180 epitope, determined the relative amounts of CP169e180 epitope in two commercially available vaccines, and analyzed the influence of the epitope level on the induction of neutralizing antibody.

2. Materials and methods

2.1. Preparation of VLP, PCV2 recombinant proteins, and peptide conjugates

PCV2 CP (amino acids [aa] 1—233) was expressed in baculovirus-infected Sf9 insect cells, as previously described [19]. The PCV2 ORF2 gene (GenBank no. EU747125) was cloned into the pFastBac expression vector (Invitrogen, Carlsbad, CA, USA) and transfected into Sf9 cells. The culture supernatant containing the recombinant baculovirus was harvested and used to infect a separate batch of Sf9 cells. After 3 days, VLPs were purified from culture supernatant by sucrose gradient ultracentrifugation.

Recombinant CP with a deletion of the N-terminal region of the protein (delN CP, aa 44—233) was expressed in Escherichia coli and purified, as described previously [12,20,21]. A synthetic CP169–180 peptide (STIDYFQPNNKRC) was chemically synthesized using Fmoc solid-phase peptide synthesis (Peptron, Inc., Daejeon, South Korea) and conjugated to bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH) [10].

2.2. Generation of recombinant chicken anti-CP169–180 antibody

White leghorn chickens were immunized with KLH-conjugated CP169–180 peptides. A phage-displayed chicken single-chain fragment (scFv) library was constructed using total RNA isolated from the bone marrow, spleen, and bursa of Fabricius of immunized chickens, as previously described [22]. A positive clone was enriched by biopanning and screened in a phage enzyme immunoassay, as described previously [23,24].

The gene encoding the selected scFv clone was subcloned into a modified mammalian expression vector encoding the C\(_\gamma\) domain of human IgG at the 3′ region [25]. The scFv-C\(_\gamma\) fusion protein (anti-CP169–180 antibody) was purified from the culture supernatants of transiently transfected HEK293F cells using KappaSelect resin (GE

---

![Fig. 1. A novel PCV2 antibody is specific to the CP169e180 epitope.](image-url)
Healthcare, London, UK), according to the manufacturer’s instructions.

2.3. Enzyme immunoassay

The wells of a 96-well microtiter plate (Corning) were coated with BSA-conjugated CP\(_{169–180}\) peptides, delN CP, and purified VLP in coating buffer (0.1 M NaHCO\(_3\), pH 8.6) and then blocked with 3% (w/v) BSA in phosphate-buffered saline (PBS). After incubation with 1 \(\mu\)g/mL of anti-CP\(_{169–180}\) antibody, horseradish peroxidase (HRP)-conjugated goat anti-human C\(_\kappa\) antibodies (Chemicon-Millipore, Billerica, MA, USA) were added to each well. After washing with 0.05% (v/v) Tween 20 in PBS (PBST), 3,3′,5,5′-tetramethyl benzidine (TMB) (GenDEPOT, Barker, TX, USA) substrate solution was added and the absorbance was measured at 650 nm with a Multiskan Ascent microplate reader (LabSystems, Helsinki, Finland) [26].

2.4. Immunoblot analysis

Dissolved proteins and BSA-conjugated CP\(_{169–180}\) peptides were boiled for 10 min in lithium dodecyl sulfate sample buffer with reducing agents (Invitrogen). The samples were then electrophoretically separated on a NuPage 12% Bis-Tris gel (Invitrogen) and transferred to a nitrocellulose membrane [27]. After blocking with 5% (w/v) skim milk in Tris-buffered saline, the membrane was incubated with 1 \(\mu\)g/mL of anti-CP\(_{169–180}\) antibody and probed with HRP-conjugated goat anti-human C\(_\kappa\) antibodies (Chemicon-Millipore). The blot was visualized using SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific, IL, USA).

2.5. Competition enzyme immunoassay using PCV2-infected pig's sera

All animal experiments were performed under the approval of the Institutional Animal Care and Use Committee of the BioPOA (permit no. BP-2015-030-2). After the collection of sera from PCV2-infected pigs and pigs with no infection history, the competition enzyme immunoassay was performed as described previously with the following appropriate modifications [25]. After pre-incubating non-infected and infected porcine sera (n = 3/group) with serially diluted anti-CP\(_{169–180}\) antibody and probed with HRP-conjugated goat anti-human C\(_\kappa\) antibodies (Chemicon-Millipore), the blot was visualized using SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific, IL, USA).

2.6. Enzyme immunoassay using two commercial vaccines

We randomly designated two of out nine commercial vaccines (Ingelvac CircoFlex [Boehringer Ingelheim Vetmedica], Porcilis PCV-one [MSD Animal Health], Circumvent PCV [Merck Animal Health], Fostera PCV [Zoetis], Suavaxx PCV [Fort Dodge Animal Health], Circovac [Merial], CircoShield [Green Cross Veterinary Products], SuíShot Circo-ONE [ChoongAng Vaccine Laboratory] and DS Circo PigVac [Daesung Microbiological LABS]) as vaccine A or vaccine B. Then vaccine A and B were diluted four-fold in coating buffer. After vigorous vortexing for 10 min, microtiter plates were coated with vaccines at 37°C for 2 h and blocked with 3% BSA in PBS.

The level of total PCV2 antigen in prepared VLP, delN CP, and the two commercial vaccines was measured by enzyme immunoassay using an anti-PCV2 polyclonal antibody (Veterinary Diagnostic Laboratory, Iowa State University, Iowa, USA) [28] and HRP-conjugated goat anti-rabbit IgG antibodies (Bethyl Laboratories, Montgomery, TX, USA), as described previously.

To monitor the CP\(_{169–180}\) epitope levels, we performed the enzyme immunoassay using the anti-CP\(_{169–180}\) antibody and HRP-conjugated goat anti-human C\(_\kappa\) antibodies (Chemicon-Millipore), as previously described.

2.7. Immunization and the analysis of immune sera

Twenty guinea pigs were randomly divided into four groups (n = 5/group). Each guinea pig was immunized intradermally with 200 \(\mu\)L of VLP, delN CP, or commercial vaccine. Four weeks after immunization, whole blood was collected and sera were prepared.

An indirect fluorescence assay (IFA) was performed using the sera and PCV2-infected PK-15 cells, as previously described [18,29]. To monitor the reactivity of sera to the CP\(_{169–180}\) epitope, enzyme immunoassays, using BSA-conjugated CP\(_{169–180}\) peptides and HRP-conjugated anti-guinea pig IgG antibodies (Bethyl Laboratories), were performed as described previously. We performed serum virus neutralization assays using PK-15 cells, as described previously [30,31].

2.8. Statistical analysis

Statistical analysis was conducted using GraphPad Prism (v5.0; GraphPad Software Inc., San Diego, CA, USA). Results are expressed as means and standard deviations of the indicated number of independent measurements. Statistical significance was determined using two-tailed unpaired Student's t tests and non-parametric Mann-Whitney's u test. Two-way analysis of variance (ANOVA) was used to analyze the relationship between the two independent factors. For all statistical analyses, p values of <0.05 were considered statistically significant.

3. Results

3.1. Novel PCV2 antibodies are specific to the CP\(_{169–180}\) epitope

A phage display library of combinatorial scFv was prepared using chickens immunized with KLH-conjugated CP\(_{169–180}\) peptides. The complexity of the library exceeded 1.2 x 10\(^9\). To enrich for scFv clones with specific reactivity to the CP\(_{169–180}\) epitope, six total rounds of biopanning were performed. For each round of biopanning, monomeric delN CP and CP\(_{169–180}\) peptides were alternately used as antigens. The N terminus of CP plays a key role in the assembly of the VLP structure. Thus, deletion of the N-terminal region exposes the CP\(_{169–180}\) epitope (del CP).

After biopanning, the reactivity of individual clones to CP\(_{169–180}\) peptide, delN CP, and PCV2 VLPs was tested by phage enzyme immunoassay. A clone was selected, and its recombinant scFv-C\(_\kappa\) fusion protein prepared using a mammalian expression system. The recombiant scFv-C\(_\kappa\) fusion protein reacted to CP\(_{169–180}\) peptide and delN CP, but not to VLPs (Fig. 1B). In an immunoblot analysis, the recombinant scFv-C\(_\kappa\) fusion protein was reactive not only to the CP\(_{169–180}\) peptide and delN CP, but also to VLPs, because the CP\(_{169–180}\) epitope on VLP was exposed by the denaturation that occurs during sample preparation (Fig. 1C).

Although the CP\(_{169–180}\) segment is too short to harbor more than one antigenic determinant, we further confirmed a number of antigenic determinants using the polyclonal sera of pigs infected with PCV2. In a competition enzyme immunoassay employing a microtiter plate coated with BSA-conjugated CP\(_{169–180}\) peptide and HRP-conjugated anti-porcine IgG antibodies, the recombinant anti-CP\(_{169–180}\) antibody almost completely inhibited the binding of naturally occurring anti-CP\(_{169–180}\) antibody to the peptide in a
PCV2-infected pig’s sera (Fig. 2). From these results, we concluded that there is only one antigenic determinant in CP169–180 residues.

3.2. Amounts of CP169–180 epitope differ in two commercial vaccines

The relative amount of PCV2 antigen in two commercially available vaccines was determined in an enzyme immunoassay, using purified VLP and the recombinant delN CP protein. The amount of coated antigen was then determined by anti-PCV2 polyclonal antibody. Because the quantity of bound antibody was not statistically different between the vaccines, we concluded that they contained similar amounts of the recombinant CP (Fig. 3A). We then determined the relative amount of CP169–180 epitope in these two vaccines with an enzyme immunoassay employing anti-CP169–180 antibody (Fig. 3B). Because we found a higher amount of anti-CP169–180 antibody bound to vaccine A-coated wells than in vaccine B-coated wells, we concluded that vaccine A contained a higher amount of CP169–180 epitope.

3.3. Humoral immune responses to two commercial vaccines corresponded to CP169–180 epitope levels

To monitor the humoral response, we collected sera from guinea pigs (n = 5/group) that were immunized with vaccines. For control sera, we also immunized with VLPs and the recombinant delN CP in parallel. To confirm successful vaccination, we performed IFA as described previously using PCV2-infected PK-15 cells [18,29]. There was no statistical difference between the antibody titer of sera obtained from animals immunized with the two vaccines. As expected, the sera of animals immunized with delN CP showed a statistically lower antibody titer compared to other groups (p < 0.05) (Fig. 3C). In an enzyme immunoassay employing a microtiter plate coated with BSA-conjugated CP169–180 peptide, sera from animals immunized with vaccine A had a significantly higher antibody titer than vaccine B-vaccinated animals (p < 0.01) (Fig. 3D). Additionally, the sera of delN CP-immunized animals had a significantly higher antibody titer than those of VLP-immunized animals (p < 0.01). Then we measured and compared the neutralizing activity of sera in an in vitro infection experiment employing PCV2 virus and PK-15 cells. The sera from vaccine B-immunized animals had a significantly higher neutralizing antibody titer than sera from vaccine A-immunized animals (p < 0.001) (Fig. 3E). Also, the sera of VLP-immunized animals showed significantly higher neutralizing activity than sera of VLP-immunized animals (p < 0.01).

4. Discussion

Since the emergence of PCV2, there has been considerable effort to produce an effective vaccine [32]. For some time, the main hurdle was efficient overexpression of CP [19,33]. Later, it was found that the immunodominant CP169–180 epitope of PCV2 is buried during viral capsid assembly and that the antibodies targeting this epitope are non-neutralizing, which is a common viral immune-evasion mechanism [14]. PCV2 infection inevitably provokes exposure to the decoy epitope and therefore is less effective at generating a protective humoral response than immunization of the subunit vaccine with a minimal amount of exposed decoy epitope [18].

Researchers had predicted that incomplete VLPs with an exposed immunodominant CP169–180 epitope can be contaminated during the preparation of subunit vaccine and drive the humoral response to produce non-neutralizing antibodies, but could not quantify the exposed immunodominant CP169–180 epitope in the subunit vaccines because of the lack of proper analytical tools [33–36]. To rectify this, we generated a monoclonal antibody specific to the immunodominant CP169–180 epitope from an antibody library generated using chickens immunized with CP169–180 peptide. This recombinant anti-CP169–180 antibody preferentially reacted to delN CP with an exposed CP169–180 epitope compared to VLP in an enzyme immunoassay (Fig. 1B). Because the length of linear B-cell epitopes can vary widely from 3 to 38 amino acids [37], we confirmed that CP169–180 peptides behave as a single epitope in a competition enzyme immunoassay. The recombinant CP169–180 antibody almost completely inhibited the binding of PCV2-infected pig sera to CP169–180 peptide.

We then used this antibody to quantify the relative amount of CP169–180 epitope in two commercially available vaccines and found that vaccine A contained significantly more decoy epitope than vaccine B. After immunization, vaccine A induced a significantly higher antibody response to decoy epitope than vaccine B, which supported the finding that vaccine B induced a higher amount of neutralizing antibody.

In summary, our research demonstrated that the amount of immunodominant decoy epitope present in PCV2 vaccine can be measured by an epitope-specific antibody. From the measured level of decoy epitope, we could predict the efficacy of a vaccine for the induction of neutralizing antibody titer. We believe that anti-CP169–180 antibody can be used to monitor the varying quality of the subunit vaccine from batch to batch.

![Fig. 2. Recombinant anti-CP169–180 antibody inhibited the binding of naturally occurring antibody.](Image)

After pre-incubation with sera from the non-infected (A) and infected pigs (B) with anti-CP169–180 antibody (n = 3/group), the mixtures were added to a CP169–180 peptide-coated microtiter plate. The amount of bound porcine antibody was measured by HRP-conjugated anti-porcine IgG antibody. Absorbance was measured at 650 nm. The results are the means ± standard deviations from the experiments, which were conducted in triplicate using the sera from three pigs (P1, P2, and P3 in each group).
Levels of CP169-180 in vaccines corresponded with humoral responses. (A) PCV2 antigen level was measured in an enzyme immunoassay using anti-PCV2 polyclonal antibody. (B) CP169-180 epitope level was measured in an enzyme immunoassay using the anti-CP169-180 antibody. (C) Anti-PCV2 antibody in the immunized sera was determined by an indirect fluorescence assay using PCV2-infected PK-15 cells (n = 5/group). (D) The amount of anti-CP169-180 antibody in the immunized sera was measured in an enzyme immunoassay using a CP169-180 peptide-coated microtiter plate. (E) Neutralizing activity of the immunized sera was measured with a virus neutralization assay. Results are the means ± standard deviations; *p < 0.05, **p < 0.01, ***p < 0.001 by two-tailed non-parametric Mann-Whitney’s U test.

Conflicts of interest

The authors have declared that there is no conflict of interest.

Acknowledgements

We would like to thank Tae-Eun Kim for the technical assistance and Taeyeub Lee for structural modeling of PCV2 using PyMOL1.3. This study was supported by the Bio-industry Technology Development Program of IPET (Korean Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries) (grant number 20110258), and the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIP) (grant number 2016M3A9B6918973).

Transparency document

Transparency document related to this article can be found online at https://doi.org/10.1016/j.bbrc.2018.01.141.

References

[1] B.B. Finlay, G. McFadden, Anti-immunology: evasion of the host immune system by bacterial and viral pathogens, Cell 124 (2006) 767–782.
[2] L. Stamatatos, L. Morris, D.R. Burton, J.R. Mascola, Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15 (2009) 866–870.
[3] M.J. Hosie, D. Pajek, A. Samman, B.J. Willett, Feline immunodeficiency virus (FIV) neutralization: a review, Viruses 3 (2011) 1870–1890.
[4] L.B. Dustin, S.B. Cashman, S.M. Laidlaw, Immune control and failure in HCV infection—tipping the balance, J. Leukoc. Biol. 96 (2014) 535–548.
[5] S.M. Szczepanek, R.W. Barrette, D. Rood, D. Alejo, L.K. Silbart, Xenoepitope substitution avoids deceptive imprinting and broadens the immune response to foot-and-mouth disease virus, Clin. Vaccine Immunol. 19 (2012) 461–467.
[6] L. Du, W. Tai, Y. Yang, Q. Zhao, Q. Zhu, S. Sun, C. Liu, X. Tao, C.K. Tseng, S. Perlman, S. Jiang, Y. Zhou, F. Li, Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines, Nat. Commun. 7 (2016) 13473.
[7] L. Yu, L. Zhang, L. Sun, J. Liu, W. Wu, C. Li, Q. Zhang, F. Zhang, C. Jin, X. Wang, Z. Bi, D. Li, M. Liang, Critical epitopes in the nucleocapsid protein of SFTS virus recognized by a panel of SFTS patients' derived human monoclonal antibodies, PLoS One 7 (2012), e38291.
[8] B. Thaa, B.C. Sinhadhi, C. Tielesch, E. Krause, M. Veit, Signal peptide cleavage from GP5 of PRRSV: a minor fraction of molecules retains the decoy epitope, a presumed molecular cause for viral persistence, PLoS One 8 (2013), e65548.
[9] L. Gillet, J.S. May, S. Colaco, P.C. Stevenson, The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization, PLoS One 2 (2007), e705.
[10] B.R. Trible, M. Kerrigan, N. Crossland, M. Potter, K. Faaberg, R. Hesse, R.R. Rowland, Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease, Clin. Vaccine Immunol. 18 (2011) 749–757.
[11] C. Yu, X. Li, J. Liu, W. Diao, L. Zhang, Y. Xiao, H. Wei, Y. Yu, Y. Yu, L. Wang, Replacing the decoy epitope of PCV2b capsid protein with a protective epitope enhances efficacy of PCV2b vaccine, Vaccine 34 (2016) 6358–6366.
[12] S. Sarker, M.C. Terron, Y. Khandokar, D. Aragao, J.M. Hardy, M. Radjainia, M. Jimenez-Zaragoza, P.J. de Pablo, F. Coulbaly, D. Luche, S.R. Raidal, J.K. Forwood, Structural insights into the assembly and regulation of distinct viral capsid complexes, Nat. Commun. 7 (2016) 13014.
[13] T. Finsterbusch, T. Steinfeldt, K. Doberstein, C. Rodner, A. Mankertz, Interactions of the replication proteins and the capsid protein of porcine circovirus type 1 and 2 with host proteins, Virology 386 (2009) 122–131.
[14] B.R. Trible, A.W. Suddith, M.A. Kerrigan, A.G. Cino-Ozuna, R.A. Hesse, R.R. Rowland, Recognition of the different structural forms of the capsid protein determines the outcome following infection with porcine circovirus type 2, J. Virol. 86 (2012) 13508–13514.
[15] B.R. Trible, R.R. Rowland, Genetic variation of porcine circovirus type 2 (PCV2) and its relevance to vaccination, pathogenesis and diagnosis, Virus Res. 164 (2012) 68–77.
application, Vet. J. 194 (2012) 151–157.

[17] A. Roldao, M.C. Mellado, L.R. Castilho, M.J. Carrondo, P.M. Alves, Virus-like particles in vaccine development, Expert Rev. Vaccines 9 (2010) 1149–1176.

[18] B.R. Trible, A. Ramirez, A. Suddith, A. Fuller, M. Kerrigan, R. Hesse, J. Niewold, B. Guo, E. Thacker, R.R. Rowland, Antibody responses following vaccination versus infection in a porcine circovirus-type 2 (PCV2) disease model show distinct differences in virus neutralization and epitope recognition, Vaccine 30 (2012) 4079–4085.

[19] L.J. Liu, T. Suzuki, H. Tsunemitsu, M. Kataoka, N. Ngata, T. Wakita, T. Miyamura, T.C. Li, Efficient production of type 2 porcine circovirus-like particles by a recombinant baculovirus, Arch. Virol. 153 (2008) 2291–2295.

[20] P.C. Wu, W.L. Lin, C.M. Wu, J.N. Chi, M.S. Chien, C. Huang, Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like-particle vaccine development, Appl. Microbiol. Biotechnol. 95 (2012) 1501–1507.

[21] M. Trundova, V. Celer, Expression of porcine circovirus 2 ORF2 gene requires codon optimized E. coli cells, Virus Genes 34 (2007) 199–204.

[22] J. Andrés-Widhopf, C. Rader, P. Steinberger, R. Fuller, C.F. Barbas 3rd, Methods for the generation of chicken monoclonal antibody fragments by phage display, J. Immunol. Meth. 242 (2000) 159–181.

[23] C.F. Barbas, Phage Display: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.

[24] H.K. Lee, J. Jin, S.J. Kim, M.J. Kang, E.C. Yi, J.E. Kim, J.R. Park, H. Kim, J. Chung, A point mutation in the heavy chain complementarity-determining region 3 (HCDR3) significantly enhances the specificity of an anti-RO51 antibody, Biochem. Biophys. Res. Commun. 493 (2017) 325–331.

[25] Y. Lee, H. Kim, J. Chung, An antibody reactive to the Gly63-Lys68 epitope of sodium dodecyl sulfate–polyacrylamide gels to unmodified nucleocapsid and radiographic detection with antibody and radiolabeled protein A, Anal. Biochem. 112 (1981) 195–203.

[26] W.N. Burnette, “Western blotting”; electrophoretic transfer of proteins from sodium dodecyl sulfate–polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radiolabeled protein A, Anal. Biochem. 112 (1981) 195–203.

[27] H.W. Seo, K. Han, Y. Oh, I. Kang, C. Park, H.E. Joo, S.H. Kim, B.H. Lee, C. Chae, Evaluation of commercial polyclonal- and monoclonal-antibody-based immunohistochemical tests for 2 genotypes of Porcine circovirus type 2 and comparison with in-situ hybridization assays, Can. J. Vet. Res. 78 (2014) 233–236.

[28] J. Li, T. Yu, X. Wang, J. Zhou, R. Gao, F. Zhang, X. Gao, S. Gao, X. Liu, Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China, Virol. J. 12 (2015) 113.

[29] G.M. Allan, D.P. Mackie, J. McNair, B.M. Adair, M.S. McNulty, Production, preliminary characterisation and applications of monoclonal antibodies to porcine circovirus, Vet. Immunol. Immunopathol. 43 (1994) 357–371.

[30] R.M. Pogranichnyy, K.J. Yoon, P.A. Harms, S.L. Swenson, J.J. Zimmerman, S.D. Sorden, Characterization of immune response of young pigs to porcine circovirus type 2 infection, Viral Immunol. 13 (2000) 143–153.

[31] K.O. Afolabi, B.C. Iveriebor, A.I. Okoh, L.C. Obi, Global status of porcine circovirus type 2 and its associated diseases in sub-saharan africa, Adv Virol 2017 (2017) 6807964.

[32] Y. Liu, Y. Zhang, L. Yao, H. Hao, X. Fu, Z. Yang, E. Du, Enhanced production of porcine circovirus type 2 (PCV2) virus-like particles in Sf9 cells by trans-lational enhancers, Biotechnol. Lett. 37 (2015) 1765–1771.

[33] P. Blanchard, D. Mahe, R. Cariolet, A. Keranitchi, M.A. Baudouard, P. Cordioli, E. Albina, A. Jestin, Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins, Vaccine 21 (2003) 4565–4575.

[34] I. Fan, C. Ju, T. Tong, H. Huang, J. Lv, H. Chen, Immunogenicity of empty capsids of porcine circovirus type 2 produced in insect cells, Vet. Res. Commun. 31 (2007) 487–496.

[35] E. Perez-Martín, S. Gomez-Sebastian, J.M. Aragüé, M. Sibila, M. Fort, M. Nofrarias, S. Kurtz, J.M. Escribano, F. Rodriguez, Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae, Vaccine 28 (2010) 2340–2349.

[36] Y. El-Manzalawy, D. Dobbs, V. Honavar, Predicting flexible length linear B-cell epitopes, Comput. Syst. Bioinf. Conf. 7 (2008) 121–132.